Development of Anticancer Ferric Complex Based on Human Serum Albumin Nanoparticles That Generate Oxygen in Cells to Overcome Hypoxia-Induced Resistance in Metal Chemotherapy حسب Ronghao Fang (16377903)

"…The <b>HSA–Fe1–O</b>_<b>2</b> NP (<b>HSA–Fe1–O</b>_<b>2</b><b>NP</b>) delivery system effectively overcame hypoxia-induced resistance in metal chemotherapy, alleviated the hypoxic condition of tumor tissues, and showed excellent tumor suppression by generating excess ROS and promoting the apoptosis of SK-N-MC tumor cells. …"

Figure 3 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors حسب Christopher T. Chen (19665314)

FIGURE 3 from Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia حسب Claire E. Pillsbury (16435223)

Figure 2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer حسب Robert J. Lake (22408833)

Supplementary Table S17 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution حسب Iros Barozzi (15113515)

Supplementary Table S3 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution حسب Iros Barozzi (15113515)

Supplementary Fig. S8 from Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa Expression حسب Azusa Tanimoto (14936243)

Supplementary Table S15 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution حسب Iros Barozzi (15113515)

Supplemental Figure S1 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model حسب Eva Tonsing-Carter (7039142)

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights حسب Daniel Nettersheim (2866097)

"…As mainly young men are suffering from GCTs, late toxicities play a major role regarding life expectancy, and the development of therapy resistance emphasizes the need for alternative therapeutic options. …"

Supplementary Table and Supplementary Figures 1 through 6 from Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer حسب Kristin J. Lastwika (3345554)

Supplementary Figures 1-5 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance حسب Lina Y. Dimberg (15077439)

Related Article from Myeloid Suppressors Decrease Melanoma Survival by Abating Tumor-Fighting T Cells حسب Rolf Kiessling (149724)

Figure 7 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer حسب Nami Yamashita (15100557)

"…<p>MUC1 and PBRM1 associate with decreases in responsiveness of TNBC tumors to chemotherapy. …"

Table3_Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.XLS حسب Leqian Ying (11832758)

"…We developed a transcriptome-based GMScore to evaluate GM activity and investigated the association of GMScore with prognosis and therapeutic resistance. Two independent HCC cohorts with transcriptome data were selected from The Cancer Genome Atlas (TCGA, n = 365) and the International Cancer Genome Consortium (ICGC, n = 231). …"

Image2_Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.TIF حسب Leqian Ying (11832758)

"…We developed a transcriptome-based GMScore to evaluate GM activity and investigated the association of GMScore with prognosis and therapeutic resistance. Two independent HCC cohorts with transcriptome data were selected from The Cancer Genome Atlas (TCGA, n = 365) and the International Cancer Genome Consortium (ICGC, n = 231). …"

Image1_Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.TIF حسب Leqian Ying (11832758)

"…We developed a transcriptome-based GMScore to evaluate GM activity and investigated the association of GMScore with prognosis and therapeutic resistance. Two independent HCC cohorts with transcriptome data were selected from The Cancer Genome Atlas (TCGA, n = 365) and the International Cancer Genome Consortium (ICGC, n = 231). …"

Table4_Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.XLS حسب Leqian Ying (11832758)

"…We developed a transcriptome-based GMScore to evaluate GM activity and investigated the association of GMScore with prognosis and therapeutic resistance. Two independent HCC cohorts with transcriptome data were selected from The Cancer Genome Atlas (TCGA, n = 365) and the International Cancer Genome Consortium (ICGC, n = 231). …"

Image2_Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.TIF حسب Leqian Ying (11832758)

"…We developed a transcriptome-based GMScore to evaluate GM activity and investigated the association of GMScore with prognosis and therapeutic resistance. Two independent HCC cohorts with transcriptome data were selected from The Cancer Genome Atlas (TCGA, n = 365) and the International Cancer Genome Consortium (ICGC, n = 231). …"

Table4_Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.XLS حسب Leqian Ying (11832758)

"…We developed a transcriptome-based GMScore to evaluate GM activity and investigated the association of GMScore with prognosis and therapeutic resistance. Two independent HCC cohorts with transcriptome data were selected from The Cancer Genome Atlas (TCGA, n = 365) and the International Cancer Genome Consortium (ICGC, n = 231). …"